SVB Leerink Downgrades Selecta Biosciences to Market Perform, Announces $1 Price Target
Portfolio Pulse from richadhand@benzinga.com
SVB Leerink analyst Joseph Schwartz has downgraded Selecta Biosciences (NASDAQ:SELB) from Outperform to Market Perform and set a price target of $1.
August 18, 2023 | 10:53 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Selecta Biosciences has been downgraded by SVB Leerink from Outperform to Market Perform with a new price target of $1.
The downgrade from Outperform to Market Perform by SVB Leerink indicates a less optimistic outlook for Selecta Biosciences. The new price target of $1 also suggests a potential decrease in the stock's value. This could negatively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100